| Baseline Characteristic |
No. of Patients |
% |
Baseline SUVmax |
| Median |
P value |
| Age |
| ≤50 |
57 |
43 |
6.3 |
0.456 |
| >50 |
73 |
56 |
6.9 |
|
| Tumor phenotype |
| Luminal A |
30 |
23 |
5.7 |
0.234 |
| Luminal B |
34 |
26 |
6.8 |
0.544 |
| Luminal B like |
26 |
20 |
7.9 |
0.136 |
| Her2 neu positive |
21 |
16 |
9.2 |
0.03* |
| Triple negative |
19 |
15 |
11.8 |
<0.001* |
| Histology |
| Ductal |
117 |
90 |
6.5 |
|
| Lobular |
9 |
7 |
5.8 |
0.453 |
| Other |
4 |
3 |
7.8 |
|
| Grade |
| 1 |
0 |
|
|
|
| 2 |
18 |
14 |
7 |
|
| 3 |
112 |
86 |
9.8 |
<0.001* |
| Proliferation index |
| Ki 67% ≤14% |
16 |
12 |
4.8 |
|
| Ki 67% ≥14% |
114 |
87 |
9.8 |
<0.001* |
| Metastatic sites |
| Visceral |
100 |
77 |
10 |
|
| Bone only |
30 |
23 |
4 |
0.005* |
| No. of metastatic sites |
| 1 |
49 |
38 |
4 |
|
| 2 |
30 |
23 |
6.8 |
0.003* |
| ≥3 |
51 |
39 |
9.8 |
|
| First therapy for MBC |
| Endocrine therapy |
31 |
24 |
4 |
|
| Targeted ± endocrinetherapy |
25 |
19 |
6.6 |
0.643 |
| Chemotherapy |
74 |
57 |
8.7 |
|
|
